Cure8 news brief
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational dual-target therapy could point to future treatment options.
Patients with moderate-to-severe Crohn's disease or ulcerative colitis, clinicians prescribing biologics or JAK inhibitors, and IBD researchers following long-term and real-world outcomes.
This release summarizes the company’s conference program and highlights selected analyses rather than reporting a single peer-reviewed study.
It emphasizes open-label extension and real-world analyses showing maintained clinical and endoscopic outcomes with risankizumab and upadacitinib through multiple years of follow-up, and mentions interim real-world response rates and claims-based comparisons.
Read closely for details presented at the meeting: look for the individual abstracts or presentations (eg, FORTIFY, AFFIRM, U-ENDURE, UPlift) to see study designs, patient populations, dosages, and exact outcome measures. Company press releases summarize findings but are not a substitute for the full abstract or peer-reviewed publication.
This is an AbbVie press release summarizing planned presentations at UEGW 2026. Details such as trial methodology, full datasets, and independent peer review are found in the individual abstracts or later publications.
Some data cited are from company-run open-label extensions and real-world/claims analyses, which have different strengths and limitations than randomized, controlled trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
